Ottobock stock holds guidance as reimbursement pressure rises

Published on 11/13/2026 at 12:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ottobock stock enters the final quarter with stronger margins and confirmed guidance. Reimbursement delays are slowing parts of the business.

Growth Holds as Reimbursement Tightens

Ottobock increased third-quarter core revenue and profitability while B2B remained the main growth engine.
The company maintained its 2026 targets but expects a more moderate seasonal contribution in the fourth quarter.
Longer reimbursement approvals are weighing on Patient Care and are expected to remain a headwind into 2027.

Ottobock, DE000BCK2223, Illustration mit AI erstellt.

Ottobock reported stronger third-quarter growth and profitability on Thursday, November 12, while cautioning that changing reimbursement frameworks are slowing the conversion of patient demand into revenue. In its Q3 release, the medical technology group said organic core revenue rose 6.4 percent in the period and 6.6 percent in the first nine months of 2026.

B2B Leads Revenue Expansion

Core revenue increased 9.0 percent year over year to 433.4 million euros in the third quarter. For the first nine months, core revenue rose 8.1 percent to 1.2518 billion euros. Products and Components, Ottobock's business-to-business segment, remained the main growth engine with organic growth of 9.9 percent in the quarter.

Regional performance was mixed. EMEA organic core revenue grew 8.0 percent, while APAC accelerated 17.9 percent after a weaker second quarter. The Americas declined 1.8 percent organically against a strong prior-year comparison. The company said softer Western European performance reflected more complex reimbursement processes and longer approval times.

Margins Improve Despite Headwinds

Underlying core EBITDA rose 13.5 percent to 120.1 million euros in the third quarter. The margin expanded by 110 basis points to 27.7 percent, supported by product mix, scale effects and disciplined cost management. Underlying net income increased 5.8 percent to 52.9 million euros.

Patient Care, the business-to-consumer segment, delivered 1.7 percent organic growth in the quarter. Ottobock said growth remained positive across regions, but the pace stayed below its ambition as longer reimbursement approvals in several European markets delayed revenue conversion. The company also cited a more complex reimbursement environment as a factor that will persist in the fourth quarter.

2026 Guidance Remains Intact

Ottobock confirmed its target for 6.0 percent to 8.0 percent organic core revenue growth in 2026 and an underlying core EBITDA margin above 27.0 percent. Management expects a more moderate seasonal uplift in the fourth quarter, but said structural demand drivers, innovation and further efficiency gains support the longer-term growth profile.

Chief Executive Oliver Jakobi said the group continued to outperform the market while reimbursement conditions became more challenging in several key markets. The company will provide its 2027 guidance together with its full-year 2026 results in March 2027. Preliminary full-year results are scheduled for February 16, 2027, followed by the annual report on March 11.